The First Targeted Therapy to Treat Cancer: The Tamoxifen Tale
- ️Wed Oct 17 2018
Lerner LJ, Holthaus FJ Jr, Thompson CR (1958) A non-steroidal estrogen antagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenyl ethanol. Endocrinology 63(3):295–318. https://doi.org/10.1210/endo-63-3-295
Lerner LJ, Jordan VC (1990) Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. Cancer Res 50(14):4177–4189
Segal SJ, Nelson WO (1958) An orally active compound with anti-fertility effects in rats. Proc Soc Exp Biol Med 98(2):431–436
Emmens CW, Cox RI, Martin L (1962) Antioestrogens. Recent Prog Horm Res 18:415
Holtkamp DE, Greslin JG, Root CA, Lerner LJ (1960) Gonadotrophin inhibiting and anti-fecundity effects of chloramiphene. Proc Soc Exp Biol Med 105:197–201
Greenblatt RB, Barfield WE, Jungck EC, Ray AW (1961) Induction of ovulation with MRL/41. Preliminary report. JAMA 178:101–104
Avigan J, Steinberg D, Vroman HE, Thompson MJ, Mosettig E (1960) Studies of cholesterol biosynthesis. I. The identification of desmosterol in serum and tissues of animals and man treated with MER-29. J Biol Chem 235:3123–3126
Laughlin RC, Carey TF (1962) Cataracts in patients treated with triparanol. JAMA 181:339–340
Palopoli FP, Feil VJ, Allen RE, Holtkamp DE, Richardson A Jr (1967) Substituted aminoalkoxytriarylhaloethylenes. J Med Chem 10(1):84–86
Harper MJ, Walpole AL (1966) Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature 212(5057):87
Lednicer D, Lyster SC, Duncan GW (1967) Mammalian antifertility agents. IV. Basic 3,4-dihydronaphthalenes and 1,2,3,4-tetrahydro-1-naphthols. J Med Chem 10(1):78–84
Lednicer D, Lyster SC, Aspergren BD, Duncan GW (1966) Mammalian antifertility agents. 3. 1-Aryl-2-phenyl-1,2,3,4-tetrahydro-1-naphthols, 1-aryl-2-phenyl-3,4-dihydronaphthalenes, and their derivatives. J Med Chem 9(2):172–176
Clark ER, Jordan VC (1976) Oestrogenic, anti-oestrogenic and fertility effects of some triphenylethanes and triphenylethylenes related to ethamoxytriphetol (MER 25). Br J Pharmacol 57(4):487–493
Abbott AC, Clark ER, Jordan VC (1976) Inhibition of oestradiol binding to oestrogen receptor proteins by a methyl-substituted analogue of tamoxifen. J Endocrinol 69(3):445–446
Jensen EV, Suzuki T, Kawashima T, Stumpf WE, Jungblut PW, DeSombre ER (1968) A two-step mechanism for the interaction of estradiol with rat uterus. Proc Natl Acad Sci U S A 59(2):632–638
Jensen EV, Suzuki T, Numata M, Smith S, DeSombre ER (1969) Estrogen-binding substances of target tissues. Steroids 13(4):417–427
Toft D, Gorski J (1966) A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization. Proc Natl Acad Sci U S A 55(6):1574–1581
Toft D, Shyamala G, Gorski J (1967) A receptor molecule for estrogens: studies using a cell-free system. Proc Natl Acad Sci U S A 57(6):1740–1743
Legha SS, Slavik M, Carter SK (1976) Nafoxidine--an antiestrogen for the treatment of breast cancer. Cancer 38(4):1535–1541
Tatee T, Carlson KE, Katzenellenbogen JA, Robertson DW, Katzenellenbogen BS (1979) Antiestrogens and antiestrogen metabolites: preparation of tritium-labeled (+/−)-cis-3-[p-(1,2,3,4-tetrahydro-6-methoxy-2-phenyl-1-naphthyl)phenoxyl]-1,2-propanediol (U-23469) and characterization and synthesis of a biologically important metabolite. J Med Chem 22(12):1509–1517
Rosati RL, Da Silva Jardine P, Cameron KO, Thompson DD, Ke HZ, Toler SM, Brown TA, Pan LC, Ebbinghaus CF, Reinhold AR, Elliott NC, Newhouse BN, Tjoa CM, Sweetnam PM, Cole MJ, Arriola MW, Gauthier JW, Crawford DT, Nickerson DF, Pirie CM, Qi H, Simmons HA, Tkalcevic GT (1998) Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J Med Chem 41(16):2928–2931. https://doi.org/10.1021/jm980048b
Haddow A, Watkinson JM, Paterson E, Koller PC (1944) Influence of synthetic oestrogens on advanced malignant disease. Br Med J 2(4368):393–398
Haddow A (1970) David A. Karnofsky memorial lecture. Thoughts on chemical therapy. Cancer 26(4):737–754
Walpole AL, Paterson E (1949) Synthetic oestrogens in mammary cancer. Lancet 2(6583):783–786
Haddow A, Watkinson JM, Paterson E, Koller PC (1944) Influence of synthetic oestrogens upon advanced malignant disease. Br Med J 1944:393–398
Hill GB (2016) Alderley Park discovered. Palatine Books, Lancaster
Cole MP, Jones CT, Todd ID (1971) A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer 25(2):270–275
Bedford GR, Richardson DN (1966) Preparation and identification of cis and trans isomers of a substituted triarylethylene. Nature 212:733–734. https://doi.org/10.1038/212733b0
Kilbourn BT, Mais RHB, Owston PG (1968) Identification of isomers of a substituted triarylethylene: the crystal structure of 1-p-(2-dimethylaminoethoxyphenyl)-1,2-cis-diphenylbut-1-ene hydrobromide. Chem Commun:291
DiPietro DL, Sanders FJ, Goss DA (1969) Effect of cis and trans isomers of clomiphene citrate on uterine hexokinase activity. Endocrinology 84(6):1404–1408. https://doi.org/10.1210/endo-84-6-1404
Harper MJ, Walpole AL (1967) A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J Reprod Fertil 13(1):101–119
Harper MJ, Walpole AL (1967) Mode of action of I.C.I. 46,474 in preventing implantation in rats. J Endocrinol 37(1):83–92
Labhsetwar AP (1970) Role of oestrogen in spontaneous ovulation demonstrated by use of an antagonist of oestrogen, ICI 46,474. Nature 225(5227):80–81
Labhsetwar AP (1970) Role of estrogens in ovulation: a study using the estrogen-antagonist, I.C.I. 46,474. Endocrinology 87(3):542–551. https://doi.org/10.1210/endo-87-3-542
Labhsetwar AP (1971) Effects of an antioestrogen on the corpus luteum of rabbits and rats. J Reprod Fertil 25(2):295–297
Labhsetwar AP (1972) Role of estrogens in spontaneous ovulation: evidence for the positive feedback in hamsters. Endocrinology 90(4):941–946. https://doi.org/10.1210/endo-90-4-941
Klopper A, Hall M (1971) New synthetic agent for the induction of ovulation: preliminary trials in women. Br Med J 1(5741):152–154
Williamson JG, Ellis JD (1973) The induction of ovulation by tamoxifen. J Obstet Gynaecol Br Commonw 80(9):844–847
Jordan VC (2014) Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer. Endocr Relat Cancer 21(3):R235–R246. https://doi.org/10.1530/ERC-14-0092
Jordan VC (2008) Tamoxifen: catalyst for the change to targeted therapy. Eur J Cancer 44(1):30–38. https://doi.org/10.1016/j.ejca.2007.11.002
Jordan VC, Lababidi MK, Langan-Fahey S (1991) Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J Natl Cancer Inst 83(7):492–496
Fromson JM, Pearson S, Bramah S (1973) The metabolism of tamoxifen (I.C.I. 46,474). I. In laboratory animals. Xenobiotica 3(11):693–709. https://doi.org/10.3109/00498257309151594
Fromson JM, Pearson S, Bramah S (1973) The metabolism of tamoxifen (I.C.I. 46,474). II. In female patients. Xenobiotica 3(11):711–714. https://doi.org/10.3109/00498257309151595
Adam HK, Gay MA, Moore RH (1980) Measurement of tamoxifen in serum by thin-layer densitometry. J Endocrinol 84(1):35–42
Adam HK, Douglas EJ, Kemp JV (1979) The metabolism of tamoxifen in human. Biochem Pharmacol 28(1):145–147
Kemp JV, Adam HK, Wakeling AE, Slater R (1983) Identification and biological activity of tamoxifen metabolites in human serum. Biochem Pharmacol 32(13):2045–2052
Bain RR, Jordan VC (1983) Identification of a new metabolite of tamoxifen in patient serum during breast cancer therapy. Biochem Pharmacol 32(2):373–375
Jordan VC, Bain RR, Brown RR, Gosden B, Santos MA (1983) Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer. Cancer Res 43(3):1446–1450
Lien EA, Solheim E, Kvinnsland S, Ueland PM (1988) Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res 48(8):2304–2308
Lien EA, Solheim E, Lea OA, Lundgren S, Kvinnsland S, Ueland PM (1989) Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res 49(8):2175–2183
Johanning J, Kroner P, Thomas M, Zanger UM, Norenberg A, Eichelbaum M, Schwab M, Brauch H, Schroth W, Murdter TE (2018) The formation of estrogen-like tamoxifen metabolites and their influence on enzyme activity and gene expression of ADME genes. Arch Toxicol 92(3):1099–1112. https://doi.org/10.1007/s00204-017-2147-y
Jordan VC, Collins MM, Rowsby L, Prestwich G (1977) A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75(2):305–316
Allen KE, Clark ER, Jordan VC (1980) Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships. Br J Pharmacol 71(1):83–91
Dehal SS, Kupfer D (1997) CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res 57(16):3402–3406
Goetz MP, Suman VJ, Reid JM, Northfelt DW, Mahr MA, Ralya AT, Kuffel M, Buhrow SA, Safgren SL, McGovern RM, Black J, Dockter T, Haddad T, Erlichman C, Adjei AA, Visscher D, Chalmers ZR, Frampton G, Kipp BR, Liu MC, Hawse JR, Doroshow JH, Collins JM, Streicher H, Ames MM, Ingle JN (2017) First-in-human phase I study of the tamoxifen metabolite Z-endoxifen in women with endocrine-refractory metastatic breast cancer. J Clin Oncol 35(30):3391–3400. https://doi.org/10.1200/JCO.2017.73.3246
Jordan VC (2017) Endoxifen: the end, or are we at the beginning? J Clin Oncol 35(30):3378–3379. https://doi.org/10.1200/JCO.2017.74.9325
Levenson AS, Jordan VC (1997) MCF-7: the first hormone-responsive breast cancer cell line. Cancer Res 57(15):3071–3078
Lippman ME, Bolan G (1975) Oestrogen-responsive human breast cancer in long term tissue culture. Nature 256(5518):592–593
Shafie SM (1980) Estrogen and the growth of breast cancer: new evidence suggests indirect action. Science 209(4457):701–702
Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS (1986) Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci U S A 83(8):2496–2500
Bindal RD, Carlson KE, Katzenellenbogen BS, Katzenellenbogen JA (1988) Lipophilic impurities, not phenolsulfonphthalein, account for the estrogenic activity in commercial preparations of phenol red. J Steroid Biochem 31(3):287–293
Bindal RD, Katzenellenbogen JA (1988) Bis(4-hydroxyphenyl)[2-(phenoxysulfonyl)phenyl]methane: isolation and structure elucidation of a novel estrogen from commercial preparations of phenol red (phenolsulfonphthalein). J Med Chem 31(10):1978–1983
Lieberman ME, Maurer RA, Gorski J (1978) Estrogen control of prolactin synthesis in vitro. Proc Natl Acad Sci U S A 75(12):5946–5949
Lieberman ME, Jordan VC, Fritsch M, Santos MA, Gorski J (1983) Direct and reversible inhibition of estradiol-stimulated prolactin synthesis by antiestrogens in vitro. J Biol Chem 258(8):4734–4740
Jordan VC, Koch R, Langan S, McCague R (1988) Ligand interaction at the estrogen receptor to program antiestrogen action: a study with nonsteroidal compounds in vitro. Endocrinology 122(4):1449–1454. https://doi.org/10.1210/endo-122-4-1449
Jordan VC, Koch R, Mittal S, Schneider MR (1986) Oestrogenic and antioestrogenic actions in a series of triphenylbut-1-enes: modulation of prolactin synthesis in vitro. Br J Pharmacol 87(1):217–223
Jordan VC, Lieberman ME (1984) Estrogen-stimulated prolactin synthesis in vitro. Classification of agonist, partial agonist, and antagonist actions based on structure. Mol Pharmacol 26(2):279–285
Jordan VC, Lieberman ME, Cormier E, Koch R, Bagley JR, Ruenitz PC (1984) Structural requirements for the pharmacological activity of nonsteroidal antiestrogens in vitro. Mol Pharmacol 26(2):272–278
Jordan VC (1984) Biochemical pharmacology of antiestrogen action. Pharmacol Rev 36(4):245–276
Lieberman ME, Gorski J, Jordan VC (1983) An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in vitro. J Biol Chem 258(8):4741–4745
Tate AC, Greene GL, DeSombre ER, Jensen EV, Jordan VC (1984) Differences between estrogen- and antiestrogen-estrogen receptor complexes from human breast tumors identified with an antibody raised against the estrogen receptor. Cancer Res 44(3):1012–1018
Tate AC, Lieberman ME, Jordan VC (1984) The inhibition of prolactin synthesis in GH3 rat pituitary tumor cells by monohydroxytamoxifen is associated with changes in the properties of the estrogen receptor. J Steroid Biochem 20(1):391–395
Tate AC, DeSombre ER, Greene GL, Jensen EV, Jordan VC (1983) Interaction of [3H] estradiol- and [3H] monohydroxytamoxifen-estrogen receptor complexes with a monoclonal antibody. Breast Cancer Res Treat 3(3):267–277
Jordan VC (1987) Laboratory models of breast cancer to aid the elucidation of antiestrogen action. J Lab Clin Med 109(3):267–277
Wolf DM, Jordan VC (1994) The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res Treat 31(1):129–138
Jordan VC (2001) Selective estrogen receptor modulation: a personal perspective. Cancer Res 61(15):5683–5687
Levenson AS, Catherino WH, Jordan VC (1997) Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor. J Steroid Biochem Mol Biol 60(5–6):261–268
Levenson AS, Jordan VC (1998) The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res 58(9):1872–1875
Liu H, Lee ES, Deb Los Reyes A, Zapf JW, Jordan VC (2001) Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex. Cancer Res 61(9):3632–3639
Liu H, Park WC, Bentrem DJ, McKian KP, Reyes Ade L, Loweth JA, Schafer JM, Zapf JW, Jordan VC (2002) Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells. J Biol Chem 277(11):9189–9198. https://doi.org/10.1074/jbc.M108335200
MacGregor Schafer J, Liu H, Bentrem DJ, Zapf JW, Jordan VC (2000) Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. Cancer Res 60(18):5097–5105
Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389(6652):753–758. https://doi.org/10.1038/39645
Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL (1998) The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95(7):927–937
Fanning SW, Mayne CG, Dharmarajan V, Carlson KE, Martin TA, Novick SJ, Toy W, Green B, Panchamukhi S, Katzenellenbogen BS, Tajkhorshid E, Griffin PR, Shen Y, Chandarlapaty S, Katzenellenbogen JA, Greene GL (2016) Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. elife 5. https://doi.org/10.7554/eLife.12792
Lednicer D, Babcock JC, Marlatt PE, Lyster SC, Duncan GW (1965) Mammalian antifertility agents. I. Derivatives of 2,3-diphenylindenes. J Med Chem 8:52–57
Robinson SP, Langan-Fahey SM, Johnson DA, Jordan VC (1991) Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos 19(1):36–43
Robinson SP, Langan-Fahey SM, Jordan VC (1989) Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts. Eur J Cancer Clin Oncol 25(12):1769–1776
Langan-Fahey SM, Tormey DC, Jordan VC (1990) Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur J Cancer 26(8):883–888
Gottardis MM, Jordan VC (1988) Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48(18):5183–5187
Sutherland R, Mester J, Baulieu EE (1977) Tamoxifen is a potent “pure” anti-oestrogen in chick oviduct. Nature 267(5610):434–435
Osborne CK, Coronado EB, Robinson JP (1987) Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol 23(8):1189–1196
Fan P, Agboke FA, Cunliffe HE, Ramos P, Jordan VC (2014) A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer. Eur J Cancer 50(16):2866–2876. https://doi.org/10.1016/j.ejca.2014.08.011
Fan P, Cunliffe HE, Griffith OL, Agboke FA, Ramos P, Gray JW, Jordan VC (2014) Identification of gene regulation patterns underlying both oestrogen- and tamoxifen-stimulated cell growth through global gene expression profiling in breast cancer cells. Eur J Cancer 50(16):2877–2886. https://doi.org/10.1016/j.ejca.2014.08.010
Gottardis MM, Wagner RJ, Borden EC, Jordan VC (1989) Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. Cancer Res 49(17):4765–4769
Gottardis MM, Jiang SY, Jeng MH, Jordan VC (1989) Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 49(15):4090–4093
Wakeling AE, Dukes M, Bowler J (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res 51(15):3867–3873
Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C (2002) Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20(16):3396–3403. https://doi.org/10.1200/JCO.2002.10.057
Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A (2002) Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20(16):3386–3395. https://doi.org/10.1200/JCO.2002.10.058
Howell A, Dodwell DJ, Anderson H, Redford J (1992) Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol 3(8):611–617
Ravdin PM, Fritz NF, Tormey DC, Jordan VC (1988) Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res 48(4):1026–1029
Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, Tormey DC (1991) Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst 83(20):1488–1491
Jordan VC, Fritz NF, Tormey DC (1987) Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III. Cancer Res 47(16):4517–4519
Jordan VC (1990) Long-term adjuvant tamoxifen therapy for breast cancer. Breast Cancer Res Treat 15(3):125–136
Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351(9114):1451–1467
Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717. https://doi.org/10.1016/S0140-6736(05)66544-0
Jordan VC (2014) Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy. J Natl Cancer Inst 106(11):dju296. https://doi.org/10.1093/jnci/dju296
Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov NV, Wolmark N, Wickerham DL, Fisher ER et al (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320(8):479–484. https://doi.org/10.1056/NEJM198902233200802
Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschenes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J, Lickley HL (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88(21):1529–1542
Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF, EBCTCG (2017) 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377(19):1836–1846. https://doi.org/10.1056/NEJMoa1701830
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Muller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrutia G, Valentini M, Wang Y, Peto R, Adjuvant Tamoxifen: Longer Against Shorter Collaborative G (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816. https://doi.org/10.1016/S0140-6736(12)61963-1
Schiavon G, Smith IE (2014) Status of adjuvant endocrine therapy for breast cancer. Breast Cancer Res 16(2):206
Jordan VC (1991) Prolonged adjuvant tamoxifen: a beginning not the end. Ann Oncol 2(7):481–484
Jordan VC (1976) Effect of tamoxifen (Ici 46,474) on initiation and growth of Dmba-induced rat mammary carcinomata. Eur J Cancer 12(6):419–424. https://doi.org/10.1016/0014-2964(76)90030-X
Cuzick J, Baum M (1985) Tamoxifen and contralateral breast cancer. Lancet 2(8449):282
Lacassagne A (1936) Hormonal pathogenesis of adenocarcinoma of the breast. Am J Cancer 27(2):217–228. https://doi.org/10.1158/ajc.1936.217
Powles TJ, Hardy JR, Ashley SE, Farrington GM, Cosgrove D, Davey JB, Dowsett M, McKinna JA, Nash AG, Sinnett HD et al (1989) A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 60(1):126–131
Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97(22):1652–1662. https://doi.org/10.1093/jnci/dji372
Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, Rotmensz N, Boyle P (1998) Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian tamoxifen prevention study. Lancet 352(9122):93–97
Smith SG, Foy R, McGowan JA, Kobayashi LC, DeCensi A, Brown K, Side L, Cuzick J (2017) Prescribing tamoxifen in primary care for the prevention of breast cancer: a national online survey of GPs’ attitudes. Br J Gen Pract 67(659):e414–e427. https://doi.org/10.3399/bjgp17X689377
Jensen EV, Block GE, Smith S, Kyser K, DeSombre ER (1971) Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst Monogr 34:55–70
McGuire W, Carbone P, Sears M, Escher G (1975) Estrogen receptors in human breast cancer: an overview. In: WL MG, Carbone PP, Vollmer EP (eds) Estrogen receptors in human breast cancer. Raven Press, New York
Consensus conference. Adjuvant chemotherapy for breast cancer (1985) JAMA 254(24):3461–3463
Terenius L (1971) Structure-activity relationships of anti-oestrogens with regard to interaction with 17-beta-oestradiol in the mouse uterus and vagina. Acta Endocrinol 66(3):431–447
Jordan VC (2006) Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol 147(Suppl 1):S269–S276. https://doi.org/10.1038/sj.bjp.0706399
Jordan VC (1988) The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole. Breast Cancer Res Treat 11(3):197–209
Carter SB (1967) Effects of cytochalasins on mammalian cells. Nature 213(5073):261–264
Welshons WV, Lieberman ME, Gorski J (1984) Nuclear localization of unoccupied oestrogen receptors. Nature 307(5953):747–749
Welshons WV, Grady LH, Judy BM, Jordan VC, Preziosi DE (1993) Subcellular compartmentalization of MCF-7 estrogen receptor synthesis and degradation. Mol Cell Endocrinol 94(2):183–194
Herbst AL, Griffiths CT, Kistner RW (1964) Clomiphene citrate (Nsc-35770) in disseminated mammary carcinoma. Cancer Chemother Rep 43:39–41
Huggins C, Grand LC, Brillantes FP (1961) Mammary cancer induced by a single feeding of polymucular hydrocarbons, and its suppression. Nature 189:204–207
Hunter RE, Longcope C, Jordan VC (1980) Steroid hormone receptors in adenocarcinoma of the endometrium. Gynecol Oncol 10(2):152–161
Emmens CW (1971) Compounds exhibiting prolonged antioestrogenic and antifertility activity in mice and rats. J Reprod Fertil 26(2):175–182
Emmens CW, Carr WL (1973) Further studies of compounds exhibiting prolonged antioestrogenic and antifertility activity in the mouse. J Reprod Fertil 34(1):29–40
Jordan VC (1975) Prolonged antioestrogenic activity of ICI 46, 474 in the ovariectomized mouse. J Reprod Fertil 42(2):251–258
Jordan VC, Koerner S (1975) Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor. Eur J Cancer 11(3):205–206
Jordan VC, Allen KE (1980) Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 16(2):239–251
Jordan VC, Allen KE, Dix CJ (1980) Pharmacology of tamoxifen in laboratory animals. Cancer Treat Rep 64(6–7):745–759
Jordan VC, Dix CJ, Allen KE (1979) The effectiveness of long term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer. In: Salmon SE, Jones SE (eds) Adjuvant therapy of cancer II. Grune and Stratton, New York, pp 19–26
Jordan VC (2016) A retrospective: on clinical studies with 5-fluorouracil. Cancer Res 76(4):767–768. https://doi.org/10.1158/0008-5472.CAN-16-0150
Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation (1985) Lancet 1(8433):836–840
Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh (1987) Lancet 2(8552):171–175
Colletta AA, Benson JR, Baum M (1994) Alternative mechanisms of action of antioestrogens. Breast Cancer Res Treat 31(1):5–9
Early Breast Cancer Trialists’ Collaborative G, Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784. https://doi.org/10.1016/S0140-6736(11)60993-8